Bespak Share Discussion Threads

[monkeyjuice] 09/9/2005 08:42

An FDA advisory committee has recommended that the FDA approve Exubera. Generally the FDA go along with whatever the advisory committe say.

Bespak will make the Exubera device for Pfizer and Sanofi-Aventis if approved, and this is predicted be worth over $37,000,000 in sales for BPK.(per annum)

[tpaulbeaumont] 09/9/2005 08:26

SO can you guys just boil-it-down and explain why its jumped this AM?

[waldron] 08/9/2005 07:15

AGM Statement

RNS Number:9825Q
Bespak PLC
08 September 2005


For immediate release 8 September 2005


Bespak plc

ANNUAL GENERAL MEETING


The Annual General Meeting of Bespak plc (LSE: BPK), the specialty medical
devices company, is being held today at which John Robinson, Chairman, will make
the following statement:

"Bespak solidly delivered its sales and profit plan in the year ended 30 April
2005, increasing earnings per share before exceptionals by 6% to 32.8p on a 5%
decline in turnover to #79.4m. Operating cash flow increased 8% and the Group
finished the year with net cash of #17.4m.

"Trading in the first quarter of the current financial year has been
encouraging. Closure of the manufacturing facility in the USA has progressed to
plan and the Group remains confident in its outlook for the year."



For further information please call:

Bespak plc [phone]
Mark Throdahl - Chief Executive
Martin Hopcroft - Group Finance Director

Buchanan Communications [phone]
Tim Thompson / Mark Court / Mary-Jane Johnson



This information is provided by RNS
The company news service from the London Stock Exchange
END

AGMSSIFWWSISESU

[waldron] 13/7/2005 09:43

LONDON (AFX) - Bespak PLC's chief executive Mark Throdahl said he expects
the company will make a "substantive acquisition" in the next 12-18 months, as
the medical device maker seeks to reduce its reliance on pharmaceuticals and
their associated long approval processes, and focus on medical devices.
Throdahl said he has been encouraged by the number of good targets that have
been found, with some as small as 10 mln stg, and some in the 25 mln stg range.
Acquisitions will be funded from the group's 17.4 mln stg cash pile, he said,
but equity would be considered on larger deals.
"The real goal here is to allow us to generate more consistent growth
because we are not a hostage to fortune to ever lengthening regulatory approval
on new drugs," the chief executive told reporters on a conference call.
"We are working very hard on this and we would have every expectation that
in the next 12-18 months we will have made a substantive acquisition. But of
course the timing of this is very unpredictable," he added.
Bespak has two division, its respiratory business, which designs,
manufactures and sells devices and components used to deliver inhaled drugs, and
its device and manufacturing services unit, which provides a range of services
to pharma and drug delivery companies.
It is the latter division the group wants to bulk up. Medical devices
typically take around six months to get the green light from regulators,
compared to pharmaceuticals which can sometimes take years.
For example, the company is waiting for Pfizer's new inhaled insulin Exubura
to get the nod from Europe and the US so it can ramp up production.
Bespak, in conjunction with Nektaris, has developed the manufacturing
process for the inhaler that will be used to deliver Exubera, the first inhaled
therapy to treat diabetes. Throdahl said the plant has been inspected by
regulators and is ready to go.
The ceo was speaking as the company announced annual results that revealed
largely flat annual profit of 11.5 mln stg, beating forecasts.
Finance director Martin Hopcroft told AFX News that the group's house broker
has pencilled in 11 mln stg pretax profit before exceptionals this year, and
earnings of 29.4 pence per share, which he said he is comfortable with.
At 9.00 am Bespak shares were unchanged at 526 pence, valuing the group at
141 mln stg. The stock is flat on the year, and has advanced 3.1 pct in the last
12 months.
[e-mail]
ab/har

[maywillow] 21/3/2005 16:51

RNS Number:0293K
Bespak PLC
21 March 2005


For immediate release 21 March 2005


Bespak plc

Bespak and airPharma Sign Collaboration Deal for New Dry Powder Device

Bespak plc (LSE: BPK), a leader in specialty medical devices, is pleased to
announce that an agreement with airPharma, a US-based specialty respiratory
pharmaceutical company, has been signed to develop and manufacture a new
inhalation device for the dry powder formulation of Zofac(TM) (Pumactant), a
treatment for asthma. As a leading developer of innovative drug delivery
technologies, Bespak will create a clinical device based upon technology
airPharma licensed from UK-based Britannia Pharmaceuticals, Ltd.

Doses of Pumactant reaching 100mg have been successfully delivered from a
laboratory based delivery system and a more portable device is now required.
airPharma will utilize Bespak's expertise in concept creation and rapid
prototyping to develop refined inhalation delivery devices for airPharma's Zofac
(TM) phase II clinical studies which are scheduled for later this year. Bespak
has over 30 years experience in device development and will be providing design,
development, scientific, and manufacturing services to ensure the 'best design
fit' for airPharma's requirements.

airPharma's novel therapy is targeted to treat attacks triggered by allergens or
other inhaled materials which affect about half the 55 million asthma patients
worldwide. Zofac(TM) is a protein free synthetic surfactant made from naturally
occurring phospholipids. When inhaled, the Zofac(TM) powder is believed to
create a "barrier" that may protect the lungs from inhaled allergens, dust and
other environmental particulates.

Mark Throdahl, Chief Executive Officer of Bespak, commented: "Once again our
expertise in device development has brought us together with a company seeking
an innovative solution to a new medical therapy. This agreement allows Bespak
and airPharma to demonstrate what can be achieved by early partnership with a
leading device manufacturer."

Doug Dockhorn, airPharma's founder and Chief Executive Officer, stated: "We are
excited to be working with one of the leading experts in the area of innovative
drug delivery device development. We have the opportunity to develop a radical,
new, high-volume drug delivery system that will not only benefit asthma
sufferers, but will also open the door for delivery of vaccines, gene therapies,
and other large molecules."

For further information please call:

Bespak plc
Mark Throdahl - Chief Executive [phone]
Martin Hopcroft - Group Finance Director

Buchanan Communications [phone]
Tim Thompson / Mark Court / Mary-Jane Johnson


Notes for Editors:

About Bespak plc

Bespak, a specialty medical devices company, is at the forefront of developing
new delivery systems for the pharmaceutical industry. The company has a product
range covering metered dose inhalers, dry powder devices, actuators and
compliance aids. The company also develops and manufactures drug delivery
devices for leading global pharmaceutical companies. The group, which has
facilities in King's Lynn and Milton Keynes in the UK and in Cary, North
Carolina, in the USA. is a public company quoted on the Official list of the
London Stock Exchange (LSE: BPK). For more information, please visit
www.bespak.com.

About airPharma

airPharma is a specialty pharmaceutical company focused on commercializing
products that address unmet needs in respiratory diseases. The company is
developing a portfolio of branded respiratory products. Dr. Robert Dockhorn and
Doug Dockhorn founded the company in 2002. Prior to airPharma, the Dockhorns
built their previous company, IMTCI, into the leader in conducting respiratory
clinical studies. airPharma is privately held and is located in Overland Park,
Kansas, USA. For more information - www.air-pharma.com.




This information is provided by RNS
The company news service from the London Stock Exchange
END

AGRPUUGCWUPAGQG


Bespak(BPK)

[katie priceless] 18/1/2005 15:47

Will the weak Dollar effect they US sales? bid price down 5p.

[kiwihope] 18/1/2005 09:09

Interims tomorrow.

[katie priceless] 06/12/2004 09:20

Up 5p on no volume this morning and no news. Are their results out this month ,also how is the falling dollar effecting U S sales?

[kermit] 01/12/2004 23:21

I wish you well TB.

Now lets hope that Euro approval is not to far away and then US. I truely beleive that with Euro approval these shares could touch £6 and with US a £10 is not out of the question. And is thats not enough then you can always pick up your 4% divi a year.

[tiltonboy] 01/12/2004 19:37

Kermit,

I picked up a fiver at 493p.

tiltonboy

[kermit] 01/12/2004 19:24

Look at NKTR in the states.

Pizer came out yesterday at a conference and said that Euro approval looks like a done deal and US will be applied for in early 2005

[katie priceless] 01/12/2004 13:15

Up 16p today, any news ?

[katie priceless] 28/11/2004 09:45

How will the falling dollar effect the sales?

[kiwihope] 28/10/2004 08:52

Lucky timing ... been watching these for months and bought yesterday on narrowing spread ...

[katie priceless] 21/10/2004 22:35

They new broker must be supporting the price.

[katie priceless] 04/10/2004 19:02

Volume 167,000 today most marked down as sells but the mm have not lowed the price.

[katie priceless] 03/10/2004 11:43

Who's shorting these shares ? why a new broker ?

[jimbill] 09/9/2004 15:53

all buys today imho. I bought at £4.59 - showed up as a sell!!

[aldwickk] 20/8/2004 11:54

128,000. buy yestaday.

[aldwickk] 08/8/2004 23:06

it's gone ex-div, should have known.

[aldwickk] 06/8/2004 16:17

After weeks of no movement it goes down today, is it just the fall- off in the u. s. market today, to blame.

[aldwickk] 23/7/2004 12:48

Can anybody tell me why are all the buys marked unknown, bought some last week and that was marked unknown.

[waldron] 08/7/2004 07:00

Device will 'transform' Bespak

Charlotte Moore
Thursday July 8, 2004
The Guardian

Bespak, the British medical devices group, reported a sharp rise in profits and promised a "transformational" change in the company with the launch of the first inhaled insulin device.
Two big pharmaceutical companies - Pfizer and Aventis - are developing the first inhaled insulin device to treat diabetes, known as Exubera, which Bespak will be manufacturing.

"The launch of this device will be transformational to the company. We hope to produce double digit sales and profit growth over three to five years once the product has been brought to market," said Mark Throdahl, chief executive.

Profit before tax for the year ending May 1 2004 almost tripled to £9.1m even though sales declined by 6% to £83.2m. The company said it had cut costs by £9m.

Pfizer and Aventis have filed an application for approval of Exubera with the European authorities but have yet to do so in America. The product was extremely well received by the diabetic community during trials, said Seb Jantet, an analyst at Investec.

Sales of medical devices used for asthma drugs for the most recent financial year performed well, rising by 5% compared with the previous period to £37.2m. The growth in respiratory devices is being driven by the switch from CFC propellants to a more environmentally friendly device, Mr Jantet said.

However, price reductions for the supply of a dry-powder inhaler to GlaxoSmithKline caused sales figures for the devices and manufacturing services to remain unchanged. This represents 45% of total sales. The company has warned that it expects sales for this division to continue to decline but the launch of Exubera should reverse this trend.